| abstract |
The invention relates to novel CGRP antagonists of general formulas (Ia) and (Ib) in which R1, R2, R3, R4, and R5 are defined as indicated below, the tautomers, isomers, diastereomers, enantiomers, hydrates, mixtures, and salts thereof, and the hydrates of the salts, especially the physiologically acceptable salts thereof with inorganic or organic acids or bases, medicaments containing said compounds, the use thereof, and methods for the production thereof. |